Cargando…
Nanoformulation-Based 1,2,3-Triazole Sulfonamides for Anti-Toxoplasma In Vitro Study
Toxoplasma gondii is deemed a successful parasite worldwide with a wide range of hosts. Currently, a combination of pyrimethamine and sulfadiazine serves as the first-line treatment; however, these drugs have serious adverse effects. Therefore, it is imperative to focus on new therapies that produce...
Autores principales: | Arafa, Fadwa M., Said, Heba, Osman, Doaa, Rezki, Nadjet, Aouad, Mohamed R., Hagar, Mohamed, Osman, Mervat, Elwakil, Bassma H., Jaremko, Mariusz, Tolba, Mona Mohamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460005/ https://www.ncbi.nlm.nih.gov/pubmed/37624339 http://dx.doi.org/10.3390/tropicalmed8080401 |
Ejemplares similares
-
Sulfadiazine analogs: anti-Toxoplasma in vitro study of sulfonamide triazoles
por: Arafa, Fadwa M, et al.
Publicado: (2023) -
Synthesis, Characterization and Nanoformulation of Novel Sulfonamide-1,2,3-triazole Molecular Conjugates as Potent Antiparasitic Agents
por: Aljohani, Faizah S., et al.
Publicado: (2022) -
1,2,3-Triazole-Benzofused Molecular Conjugates as Potential Antiviral Agents against SARS-CoV-2 Virus Variants
por: Al-Humaidi, Jehan Y., et al.
Publicado: (2022) -
Novel 1,2,3-Triazole-sulphadiazine-ZnO Hybrids as Potent Antimicrobial Agents against Carbapenem Resistant Bacteria
por: Aljohani, Faizah S., et al.
Publicado: (2022) -
Novel Hybrid 1,2,4- and 1,2,3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking
por: El Sawy, Maged A., et al.
Publicado: (2022)